Friday, 19 April 2024
Arsanis Inc. Common Stock
-
Overlay
-
Indicators
-
Settings
-
Period
13:22 | 17/3/18
The Lincolnian Online
Arsanis logo Arsanis, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections.
more»
01:00 | 15/3/18
Business Wire
WALTHAM, Mass. & VIENNA--(BUSINESS WIRE)--Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the United States ...
more»
04:00 | 10/3/18
StreetInsider.com
This Registration Statement on Form S-8, relating to the 2017 Equity Incentive Plan of Arsanis, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration ...
more»
01:00 | 10/3/18
Business Wire
Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases.
more»
01:56 | 6/3/18
Business Wire
WALTHAM, Mass. & VIENNA--(BUSINESS WIRE)--Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced today that CEO René Russo ...
more»
04:45 | 25/2/18
StockNewsTimes
Shares of Arsanis Inc (NASDAQ:ASNS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports.
more»
More notable recent Arsanis, Inc. (NASDAQ:ASNS) news were published by: Reuters.com which released: “BRIEF-Arsanis Inc now sees IPO of 4 mln shares of common stock” on November 15, 2017, also Streetinsider.com with their article: “Cantor Fitzgerald ...
more»
01:22 | 21/2/18
StockNewsTimes
ValuEngine raised shares of Arsanis from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
more»
10:11 | 15/2/18
StreetInsider.com
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. Cantor Fitzgerald initiates coverage on Arsanis Inc. (NASDAQ: ASNS) with a Overweight rating and a price target of $26.00 ...
more»
03:43 | 6/2/18
The Ledger Gazette
Shares of Arsanis Inc (NASDAQ:ASNS) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports.
more»